BPG is committed to discovery and dissemination of knowledge
Review
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. Sep 18, 2023; 11(6): 266-276
Published online Sep 18, 2023. doi: 10.13105/wjma.v11.i6.266
History, origin, transmission, genome structure, replication, epidemiology, pathogenesis, clinical features, diagnosis, and treatment of COVID-19: A review
Rajesh Kumar Mokhria, Jitender Kumar Bhardwaj, Ashwani Kumar Sanghi
Rajesh Kumar Mokhria, Department of School Education, Government Model Sanskriti Senior Secondary School, Chulkana, Panipat, 132101, Haryana, India
Jitender Kumar Bhardwaj, Reproductive Physiology Laboratory, Department of Zoology, Kurukshetra University, Kurukshetra 136119, Haryana, India
Ashwani Kumar Sanghi, School of Allied and Health Sciences, MVN University, Palwal 121102, Haryana, India
Author contributions: Mokhria RK, Bhardwaj JK and Sanghi AK designed the outline, collected the data, wrote the manuscript, and proofread the paper.
Conflict-of-interest statement: All the author declare no conflict of interest for this article.
Corresponding author: Rajesh Kumar Mokhria, PhD, Lecturer, Government Model Sanskriti Senior Secondary School, Chulkana, Panipat, 132101, Haryana, India. mokhria79@gmail.com
Received: April 4, 2023
Peer-review started: April 4, 2023
First decision: May 15, 2023
Revised: July 15, 2023
Accepted: July 25, 2023
Article in press: July 25, 2023
Published online: September 18, 2023
Processing time: 162 Days and 0.3 Hours
Core Tip

Core Tip: An acute respiratory illness (COVID-19) is caused by a new coronavirus designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 belongs to β-coronaviruses, and it shares the same genome as coronavirus seen in bats. It primarily disseminates by means of the respiratory passage. Much evidence revealed human-to-human transmission. Fever, cough, tiredness, and gastrointestinal illness are the manifestations in COVID-19-infected persons. Various antiviral therapies are accessible for the handling of COVID-19 disease.